Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

June 14, 2023

Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors

International Conference on Malignant Lymphoma (ICML) 2023
CTCL LGL-L PTCL Solid Tumors
Read More
June 6, 2023

Pulse Dosing of Potent and Selective Heterobifunctional MDM2 Degrader KT-253 Drives Tumor Regression and Demonstrates Differentiated Pharmacology Compared to p53/MDM2 Small Molecule Inhibitors

European Hematology Association (EHA) 2023 Hybrid Congress
Liquid Tumors
Read More
December 12, 2022

Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader

American Society of Hematology Annual Meeting and Expo
CTCL
Read More
December 12, 2022

Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of IRAKIMiD sand BCL2 Inhibition

American Society of Hematology Annual Meeting and Expo
MYD88 Tumors
Read More
December 11, 2022

Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the treatment of Acute Myeloid Leukemia

American Society of Hematology Annual Meeting
Liquid Tumors
Read More
October 27, 2022

Discovery of a First-In-Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP-53 Wt AML & Solid Tumors

5th Annual Targeted Protein Degradation (TPD) Summit
Liquid Tumors Solid Tumors
Read More
October 19, 2022

KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo

20th Annual Discovery on Target Conference
Liquid Tumors Solid Tumors
Read More
August 24, 2022

Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications

ACS Fall 2022
MYD88 Tumors
Read More
June 26, 2022

Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology

37th ACS National Medicinal Chemistry Symposium
MYD88 Tumors
Read More
June 7, 2022

Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications

Targeting protein degradation 3 – from discovery to the clinic (TPD3)
MYD88 Tumors
Read More